Dr. David Kovacich, M.D
NPI: 1447221981
Total Payments
$666,196
2024 Payments
$20,256
Companies
32
Transactions
1,024
Medicare Patients
9,984
Medicare Billing
$568,841
Payment Breakdown by Category
Other$627,019 (94.1%)
Food & Beverage$21,198 (3.2%)
Travel$17,521 (2.6%)
Consulting$420.50 (0.1%)
Education$37.84 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $627,019 | 274 | 94.1% |
| Food and Beverage | $21,198 | 601 | 3.2% |
| Travel and Lodging | $17,521 | 142 | 2.6% |
| Consulting Fee | $420.50 | 2 | 0.1% |
| Education | $37.84 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $243,251 | 249 | $0 (2024) |
| Amgen Inc. | $190,795 | 269 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $139,610 | 220 | $0 (2024) |
| Amarin Pharma Inc. | $70,056 | 75 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $16,336 | 17 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $2,245 | 24 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,177 | 51 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $589.27 | 27 | $0 (2024) |
| PFIZER INC. | $421.10 | 29 | $0 (2024) |
| Vifor Pharma, Inc. | $200.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,256 | 74 | Amgen Inc. ($10,474) |
| 2023 | $50,507 | 114 | Amgen Inc. ($21,402) |
| 2022 | $59,278 | 128 | Janssen Pharmaceuticals, Inc ($40,249) |
| 2021 | $12,428 | 34 | Janssen Pharmaceuticals, Inc ($8,490) |
| 2020 | $28,705 | 41 | Amarin Pharma Inc. ($12,718) |
| 2019 | $146,130 | 183 | Janssen Pharmaceuticals, Inc ($73,611) |
| 2018 | $118,832 | 172 | Amgen Inc. ($58,465) |
| 2017 | $230,060 | 278 | Novartis Pharmaceuticals Corporation ($92,654) |
All Payment Transactions
1,024 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $2.09 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: DIABETES | ||||||
| 12/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: Cardiology | ||||||
| 11/25/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/22/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Cardiology | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/15/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Not Applicable | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.17 | General |
| Category: Cardiovascular | ||||||
| 11/01/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: Cardiology | ||||||
| 10/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: DIABETES | ||||||
| 10/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Cardiology | ||||||
| 10/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: Cardiology | ||||||
| 09/30/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $16.06 | General |
| 09/24/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Travel and Lodging | Cash or cash equivalent | $174.20 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/24/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/09/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.96 | General |
| Category: Cardiovascular | ||||||
| 08/27/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,914.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/26/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $123.48 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/08/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $94.86 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/08/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Not Applicable | ||||||
| 08/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $10.89 | General |
| Category: Cardiology | ||||||
| 08/01/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,399.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/30/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $209.60 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 2,534 | 2,883 | $485,293 | $151,652 |
| 2022 | 17 | 2,329 | 2,649 | $436,860 | $137,219 |
| 2021 | 17 | 2,580 | 2,895 | $404,503 | $144,066 |
| 2020 | 23 | 2,541 | 2,795 | $386,793 | $135,904 |
Total Patients
9,984
Total Services
11,222
Medicare Billing
$568,841
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 542 | 642 | $160,500 | $40,681 | 25.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 61 | 149 | $74,094 | $24,083 | 32.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 421 | 426 | $58,788 | $21,487 | 36.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 89 | 148 | $30,110 | $13,275 | 44.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 99 | 174 | $24,206 | $10,034 | 41.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 153 | 153 | $26,334 | $8,470 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 94 | 105 | $27,647 | $7,875 | 28.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 63 | 65 | $22,100 | $6,543 | 29.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 39 | 39 | $14,040 | $3,684 | 26.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 28 | 28 | $11,914 | $3,443 | 28.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 184 | 184 | $8,096 | $2,860 | 35.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 379 | 388 | $6,984 | $2,181 | 31.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $5,280 | $2,099 | 39.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 189 | 189 | $5,859 | $1,932 | 33.0% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 29 | 29 | $3,712 | $1,465 | 39.5% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 27 | 27 | $1,242 | $516.51 | 41.6% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2023 | 12 | 12 | $1,332 | $400.09 | 30.0% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 29 | 29 | $1,479 | $383.04 | 25.9% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 52 | 52 | $1,092 | $120.00 | 11.0% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 22 | 22 | $484.00 | $119.90 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 501 | 584 | $146,000 | $37,312 | 25.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 423 | 427 | $58,926 | $21,666 | 36.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 107 | 212 | $38,796 | $16,293 | 42.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 37 | 82 | $39,852 | $12,800 | 32.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 166 | 166 | $27,888 | $9,491 | 34.0% |
About Dr. David Kovacich, M.D
Dr. David Kovacich, M.D is a Advanced Heart Failure and Transplant Cardiology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447221981.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kovacich, M.D has received a total of $666,196 in payments from pharmaceutical and medical device companies, with $20,256 received in 2024. These payments were reported across 1,024 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($627,019).
As a Medicare-enrolled provider, Kovacich has provided services to 9,984 Medicare beneficiaries, totaling 11,222 services with total Medicare billing of $568,841. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Advanced Heart Failure and Transplant Cardiology
- Other Specialties Cardiovascular Disease
- Location Indianapolis, IN
- Active Since 02/01/2006
- Last Updated 10/09/2023
- Taxonomy Code 207RA0001X
- Entity Type Individual
- NPI Number 1447221981
Products in Payments
- XARELTO (Drug) $243,259
- Repatha (Biological) $190,675
- ENTRESTO (Drug) $138,866
- Vascepa (Drug) $70,056
- PRALUENT ALIROCUMAB INJECTION (Biological) $16,211
- PRALUENT (Drug) $1,972
- LEQVIO (Drug) $743.74
- ELIQUIS (Drug) $706.71
- BRILINTA (Drug) $702.59
- FARXIGA (Drug) $438.76
- MULTAQ (Drug) $273.73
- Veltassa (Drug) $218.27
- JARDIANCE (Drug) $215.32
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $139.15
- EVKEEZA (Biological) $125.00
- NEXLIZET (Drug) $125.00
- Mitra Clip system (Device) $120.50
- CAMZYOS (Drug) $120.11
- Arcalyst (Drug) $95.71
- GoNitro (Drug) $94.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Advanced Heart Failure and Transplant Cardiology Doctors in Indianapolis
Dr. Sashi Adigopula, M.d, M.D
Advanced Heart Failure and Transplant Cardiology — Payments: $199,338
Advanced Heart Failure and Transplant Cardiology $199,338
Rafael Garcia-Cortes, Md, MD
Advanced Heart Failure and Transplant Cardiology — Payments: $82,921
Advanced Heart Failure and Transplant Cardiology $82,921
Radha Kanneganti Perue, Mbbs, MBBS
Advanced Heart Failure and Transplant Cardiology — Payments: $12,622
Advanced Heart Failure and Transplant Cardiology $12,622
Angela Brittsan, M.d, M.D
Advanced Heart Failure and Transplant Cardiology — Payments: $8,661
Advanced Heart Failure and Transplant Cardiology $8,661
Joanna Pasley, Agnp-C, AGNP-C
Advanced Heart Failure and Transplant Cardiology — Payments: $465.37
Advanced Heart Failure and Transplant Cardiology $465.37
Polly Moore, Md, MD
Advanced Heart Failure and Transplant Cardiology — Payments: $231.39
Advanced Heart Failure and Transplant Cardiology $231.39